跳至主要内容
临床试验/NCT06202456
NCT06202456已完成4 期

A Single-arm, Multicenter Phase IV Study to Investigate the Efficacy and Safety of Huazhi Rougan Granule in the Treatment of Non-alcoholic Simple Fatty Liver (Damp-heat Obstruction Syndrome: Shi-Re-Zhong-Zu Zheng)

Shandong New Time Pharmaceutical Co., LTD1 个研究点 分布在 1 个国家目标入组 2,007 人开始时间: 2020年5月13日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
2,007
试验地点
1
主要终点
Liver-to-spleen CT ratio

研究概览

简要总结

An open Label, Single-arm, Multicenter phase IV study; There was a 2-week screening period and a 12-week / 24-week treatment period

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • ≥18 years old;
  • Those who meet the diagnostic criteria of non-alcoholic simple fatty liver and traditional chinese medicine syndrome classification of damp-heat obstruction syndrome;
  • Voluntarily sign informed consent;
  • Liver-to-spleen CT ratio < 1.0; The imaging findings of liver were consistent with the diagnostic criteria of diffuse fatty liver;
  • HbA1c≤6.5%;ALT、AST、TBil≤2×ULN;GFR≥60(ml/min/1.73m2).

排除标准

  • Fatty liver caused by chronic heart failure, malnutrition and pregnancy, encephalopathy fatty liver syndrome (Reye syndrome), B-lipoprotein deficiency, localized fatty liver; Fatty liver caused by diabetes, long-term use of hormones, enteritis, gastrointestinal postoperative chronic infection, etc.; Small intestinal bypass surgery, hepatocyte toxicity injury, chronic febrile diseases such as tuberculosis, ulcerative nodules;
  • Severe fatty liver with ascites, edema, hyponatremia and other suspected cirrhosis; Hepatitis or cirrhosis caused by viruses, drug poisoning, immune diseases and other factors;
  • Pregnant and lactating women, women of childbearing age who do not take effective contraceptive measures (such as condoms, hormonal contraceptives, intrauterine devices) or male subjects who do not want to use contraception;;
  • Patient with serious primary cardiovascular disease, kidney disease and other serious diseases that affect survival;
  • Patient with a history of cancer;
  • Patient with HCV antibody, HIV antibody positive or HBsAg positive and HBV-DNA titer positive;
  • Have a history of alcohol abuse (alcohol equivalent male≥30g/d, female ≥20g/d) or drug abuse;
  • Allergic to the components of this drug;;
  • Those who participated in other clinical investigators within 3 months prior to screening;
  • Those who with a history of diabetes;
  • Patients who had used the same traditional Chinese medicine for the treatment of non-alcoholic simple fatty liver within 2 weeks before screening (except experimental drugs);
  • The investigators consider she/he inappropriate to participate in this study.

研究组 & 干预措施

Huazhi Rougan granule

Experimental

干预措施: Huazhi Rougan granule (Drug)

结局指标

主要结局

Liver-to-spleen CT ratio

时间窗: 12 weeks

Clinical recovery: liver/spleen CT ratio ≥ 1; Obvious effect: liver/spleen CT ratio decreased by 2 grades (severe → mild); Effective: Liver/spleen CT ratio decreased by 1 grade (severe → moderate, or moderate → mild) :+ Ineffective: liver/spleen CT ratio did not change or even increased.

次要结局

  • The reduction of traditional Chinese medicine (TCM) syndrome integral(12 weeks)
  • the reduction of ALT(12 weeks)
  • the reduction of blood lipid index(12 weeks)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验